These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 6495895

  • 1. [Measurement of activated whole blood coagulation as a control parameter for heparin dosage in hemodialysis].
    Kraatz G, Lopot F.
    Z Urol Nephrol; 1984 Aug; 77(8):465-71. PubMed ID: 6495895
    [Abstract] [Full Text] [Related]

  • 2. [Individual dosage schedule of heparin therapy in chronic hemodialysis by analytic studies of blood coagulation].
    Gläser V, Anstadt M.
    Z Urol Nephrol; 1990 Mar; 83(3):133-40. PubMed ID: 2356667
    [Abstract] [Full Text] [Related]

  • 3. Clotting, activated partial thromboplastin and coagulation times in monitoring heparin therapy.
    Kurec AS, Morris MW, Davey FR.
    Ann Clin Lab Sci; 1979 Mar; 9(6):494-500. PubMed ID: 518012
    [Abstract] [Full Text] [Related]

  • 4. [Laboratory controls of heparin therapy with thrombin time, partial thromboplastin time and activated recalcification time].
    Lutze G, Presser HJ, Urbahn H.
    Z Gesamte Inn Med; 1989 Apr 15; 44(8):235-40. PubMed ID: 2662657
    [Abstract] [Full Text] [Related]

  • 5. [Heparin dosage in chronic hemodialysis (author's transl)].
    Vogel GE, Hansen W, Goldmann FL, Kopp KF.
    Med Klin; 1977 Oct 07; 72(40):1617-23. PubMed ID: 916946
    [Abstract] [Full Text] [Related]

  • 6. [Use of activated coagulation time for evaluation of the degree of heparinization and calculation of heparin pharmacokinetic parameters during hemodialysis].
    Khodas MIa, Piatnitskaia GKh, Lanskaia IM, Maksimenko VA, Savina ME.
    Urol Nefrol (Mosk); 1988 Oct 07; (3):42-8. PubMed ID: 3218006
    [No Abstract] [Full Text] [Related]

  • 7. Activated coagulation time test: a convenient monitor of heparinization for dogs used in cardiovascular research.
    Wilkerson RD, Conran PB, Greene SL.
    Lab Anim Sci; 1984 Feb 07; 34(1):62-5. PubMed ID: 6716959
    [Abstract] [Full Text] [Related]

  • 8. Effect of a sliding scale protocol for heparin on the ability to maintain whole blood activated partial thromboplastin times within a desired range in hemodialysis patients.
    Low CL, Bailie G, Morgan S, Eisele G.
    Clin Nephrol; 1996 Feb 07; 45(2):120-4. PubMed ID: 8846524
    [Abstract] [Full Text] [Related]

  • 9. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
    Harenberg J, Haaf B, Dempfle CE, Stehle G, Heene DL.
    Nephrol Dial Transplant; 1995 Feb 07; 10(2):217-22. PubMed ID: 7753456
    [Abstract] [Full Text] [Related]

  • 10. Activated partial thromboplastin time and activated coagulation time in monitoring heparinized cats.
    Greene CE, Meriwether E.
    Am J Vet Res; 1982 Aug 07; 43(8):1473-7. PubMed ID: 7103231
    [Abstract] [Full Text] [Related]

  • 11. Improved dialyzer reuse after use of a population pharmacodynamic model to determine heparin doses.
    Ouseph R, Brier ME, Ward RA.
    Am J Kidney Dis; 2000 Jan 07; 35(1):89-94. PubMed ID: 10620549
    [Abstract] [Full Text] [Related]

  • 12. Activation of coagulation during hemodialysis: effect of blood lines alone and whole extracorporeal circuit.
    Lucchi L, Ligabue G, Marietta M, Delnevo A, Malagoli M, Perrone S, Stipo L, Grandi F, Albertazzi A.
    Artif Organs; 2006 Feb 07; 30(2):106-10. PubMed ID: 16433843
    [Abstract] [Full Text] [Related]

  • 13. [Kinetics of anticoagulation in hemodialysis. Sequential study of single, intermittent and continuous heparinization].
    Ghezzi PM, Di Siena F, Palanca R, Dutto A, Cento G.
    Minerva Med; 1980 Oct 27; 71(41):2987-91. PubMed ID: 7454084
    [Abstract] [Full Text] [Related]

  • 14. Whole-blood activated coagulation time for evaluation of heparin activity during hemodialysis: a comparison of administration by single-dose and by infusion.
    Wilhelmsson S, Lins LE.
    Clin Nephrol; 1983 Feb 27; 19(2):82-6. PubMed ID: 6839556
    [Abstract] [Full Text] [Related]

  • 15. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R, Jacobs C.
    Res Vet Sci; 2001 Apr 27; 70(2):101-8. PubMed ID: 11356088
    [Abstract] [Full Text] [Related]

  • 16. Whole-blood thrombin time: a bedside method for determination of heparin activity.
    Wilhelmsson S, Lins LE.
    Clin Nephrol; 1976 Dec 27; 6(6):523-5. PubMed ID: 1009699
    [Abstract] [Full Text] [Related]

  • 17. Measurement of fibrinopeptide A in the evaluation of heparin activity and fibrin formation during hemodialysis.
    Wilhelmsson S, Asaba H, Gunnarsson B, Kudryk B, Robinson D, Bergström J.
    Clin Nephrol; 1981 May 27; 15(5):252-8. PubMed ID: 7249422
    [Abstract] [Full Text] [Related]

  • 18. [Heparin-free hemodialysis in chronic patients for temporary management of conditions with a high risk of bleeding].
    Stradtmann H, Förster S, Jalinski W.
    Z Urol Nephrol; 1988 Jul 27; 81(7):449-53. PubMed ID: 3176720
    [Abstract] [Full Text] [Related]

  • 19. Heparin kinetics during hemodialysis: variation in sensitivity, distribution volume, and dosage.
    Seifert R, Borchert W, Letendre P, Knutson R, Cipolle R.
    Ther Drug Monit; 1986 Jul 27; 8(1):32-6. PubMed ID: 3961894
    [Abstract] [Full Text] [Related]

  • 20. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.
    Esposito RA, Culliford AT, Colvin SB, Thomas SJ, Lackner H, Spencer FC.
    J Thorac Cardiovasc Surg; 1983 Feb 27; 85(2):174-85. PubMed ID: 6823136
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.